To our knowledge, our work might be the first to report the mechanism underlying the anti‐inflammatory effect of GR antagonism in DCI‐like pathology involving NLRP3 inflammasome regulation, which may provide evidence for the potential of GR antagonism in the treatment of inflammation‐related diseases. The gene discussed is NR3C1; the disease is inflammation.